Assembly Biosciences Inc stock is traded at $22.37, with a volume of 203,143. It is up +4.78% in the last 24 hours and down -1.76% over the past month. Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
Previous Close:
$21.35
Open:
$21.11
24h Volume:
203,143
Relative Volume:
0.79
Market Cap:
$455.47M
Revenue:
$71.10M
Net Income/Loss:
-$6.38M
P/E Ratio:
-
EPS:
-$1.20
Net Cash Flow:
-$39.84M
1W Performance:
+11.85%
1M Performance:
-1.76%
6M Performance:
-27.42%
1Y Performance:
-37.60%
1-Day Range:
$21.00$22.69
1-Week Range:
$20.00$22.69
52-Week Range:
$19.20$39.71
Assembly Biosciences Inc Stock (ASMB) Company Profile
Name
Assembly Biosciences IncSector
HealthcareIndustry
BiotechnologyPhone
(833) 409-4583Address
TWO TOWER PLACE, SOUTH SAN FRANCISCO, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS